Xiaojun Yan, MD
Pulmonary Disease · Brooklyn, NYNPI 1033110788
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $211,372 of the $249,376 with a category attached, or 84.8%. 31 manufacturers reported payments, led by GSK at 44.4% of the total. Reporting peaked in 2022 at $53,971 and has fallen 70.8% since, to $15,780 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 901 payments — averaging $276.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$111K
- AstraZeneca$64K
- Boehringer Ingelheim$48K
- Insmed, Inc.$13K
- Sunovion Pharmaceuticals Inc.$8K
- Sanofi$1K
- plus $5K from 25 others
What the payments were for
- Consulting fees$12,3695%
- Speaking & faculty fees$211,37285%
- Travel & lodging$1,8711%
- Food & beverage$23,2549%
- Education$5100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 181 | $110,823 |
| AstraZeneca | 209 | $63,876 |
| Boehringer Ingelheim | 151 | $47,849 |
| Insmed, Inc. | 53 | $12,599 |
| Sunovion Pharmaceuticals Inc. | 36 | $7,902 |
| Sanofi | 41 | $1,142 |
| Genentech USA, Inc. | 56 | $751 |
| Regeneron Healthcare Solutions, Inc. | 18 | $652 |
| Mylan Specialty L.p. | 25 | $541 |
| Philips North America LLC | 22 | $501 |
| Actelion Pharmaceuticals US, Inc. | 14 | $455 |
| Regeneron | 3 | $361 |
| Advanced Respiratory, Inc | 13 | $308 |
| Grifols USA, LLC | 16 | $263 |
| Inogen, Inc. | 13 | $256 |
| Mallinckrodt Hospital Products Inc. | 7 | $178 |
| ANI Pharmaceuticals, Inc. | 5 | $156 |
| Baxter Healthcare | 5 | $121 |
| Amgen(2 entities) | 5 | $107 |
| Paratek Pharmaceuticals, Inc. | 5 | $88 |
| Teva Pharmaceuticals USA, Inc. | 5 | $81 |
| Electromed, Inc. | 3 | $72 |
| Novartis | 4 | $60 |
| Pfizer | 3 | $52 |
| Optinose US, Inc. | 2 | $45 |
| Circassia Inc. | 1 | $28 |
| Viatris Specialty LLC | 1 | $28 |
| Verona Pharma, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| United Therapeutics Corporation | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$66,830
- BREZTRI$38,831
- AIRSUPRA$21,363
- OFEV$19,911
- Arikayce$10,985
- LONHALA MAGNAIR$7,521
- ANORO ELLIPTA$1,200
- FARXIGA$580
- SPIRIVA$533
- DUPIXENT$486
- TEZSPIRE$125
- BEXSERO$106
How this compares
$249,376 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 95 | $1,274,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,509 | $1,035,807 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 569 | $380,083 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $218,847 |
| Dupixent PenDupilumab | 50 | $182,146 |
| Breo ElliptaFluticasone/Vilanterol | 358 | $153,970 |
| TezspireTezepelumab-Ekko | 19 | $79,884 |
| Spiriva RespimatTiotropium Bromide | 107 | $64,294 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 104 | $63,755 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 89 | $59,093 |
| EliquisApixaban | 64 | $43,723 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,425 | $40,359 |
| Arnuity ElliptaFluticasone Furoate | 97 | $24,589 |
| Incruse ElliptaUmeclidinium Bromide | 55 | $20,708 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 127 | $16,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $47,849 | $1,397,902291 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $110,823 | $1,298,8292,123 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Airsupra, Symbicort | $63,876 | $473,027624 claims |
| Insmed, Inc.Arikayce | $12,599 | $218,84714 claims |
| PfizerEliquis | $52 | $43,72364 claims |
| Optinose US, Inc.Xhance | $45 | $12,90611 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $81 | $4,84114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Brooklyn
- Ali El AtatBrooklyn$482K
- Sunil MehraBrooklyn$388K
- Boris SagalovichBrooklyn$212K
- Chaim BernsteinBrooklyn$186K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.